Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling.
Adenylate Kinase
/ metabolism
Animals
Diet, High-Fat
Energy Metabolism
/ drug effects
Fatty Acids
/ metabolism
Hep G2 Cells
Hepatocytes
/ metabolism
Humans
Insulin Resistance
Mechanistic Target of Rapamycin Complex 2
/ metabolism
Mice, Inbred C57BL
Mice, Knockout
Mitochondria, Liver
/ metabolism
Oxidation-Reduction
Pyrazoles
/ pharmacology
Reactive Oxygen Species
/ metabolism
Receptor, Cannabinoid, CB1
/ antagonists & inhibitors
Sirtuin 1
/ metabolism
Sulfonamides
/ pharmacology
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
03
07
2018
accepted:
30
10
2018
pubmed:
7
12
2018
medline:
30
5
2020
entrez:
4
12
2018
Statut:
ppublish
Résumé
Endocannabinoids promote energy conservation in obesity, whereas cannabinoid-1 receptor (CB
Identifiants
pubmed: 30506571
doi: 10.1002/hep.30364
pmc: PMC6438767
mid: NIHMS999807
doi:
Substances chimiques
Fatty Acids
0
Pyrazoles
0
Reactive Oxygen Species
0
Receptor, Cannabinoid, CB1
0
Sulfonamides
0
Mechanistic Target of Rapamycin Complex 2
EC 2.7.11.1
Adenylate Kinase
EC 2.7.4.3
Sirtuin 1
EC 3.5.1.-
JD5037
ENZ75DG2Z6
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1535-1548Subventions
Organisme : Intramural NIH HHS
ID : Z99 AA999999
Pays : United States
Organisme : Supported by intramural funds from the National Institute on Alcohol Abuse and Alcoholism
Pays : International
Informations de copyright
Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Références
Am J Physiol. 1999 Jul;277(1):E1-10
pubmed: 10409121
Nature. 2001 Apr 12;410(6830):822-5
pubmed: 11298451
Am J Physiol Regul Integr Comp Physiol. 2003 Feb;284(2):R345-53
pubmed: 12399252
J Lipid Res. 2002 Dec;43(12):2112-22
pubmed: 12454273
J Clin Invest. 2003 Aug;112(3):423-31
pubmed: 12897210
Science. 2005 Jan 21;307(5708):384-7
pubmed: 15662004
Science. 2005 Feb 18;307(5712):1098-101
pubmed: 15718470
J Clin Invest. 2005 May;115(5):1298-305
pubmed: 15864349
J Biol Chem. 2005 Jul 1;280(26):25196-201
pubmed: 15899896
N Engl J Med. 2005 Nov 17;353(20):2121-34
pubmed: 16291982
Cell. 2008 Jan 25;132(2):171-6
pubmed: 18243090
Diabetes. 2008 Aug;57(8):2028-36
pubmed: 18477809
Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9793-8
pubmed: 18599449
J Clin Invest. 2008 Sep;118(9):3160-9
pubmed: 18677409
Acta Physiol (Oxf). 2009 May;196(1):81-98
pubmed: 19245656
Cell Metab. 2009 Apr;9(4):327-38
pubmed: 19356714
Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1162-70
pubmed: 19724020
Diabetes. 2010 Apr;59(4):926-34
pubmed: 20110567
J Clin Invest. 2010 Aug;120(8):2953-66
pubmed: 20664173
Diabetes. 2010 Nov;59(11):2826-36
pubmed: 20739683
FASEB J. 2011 May;25(5):1664-79
pubmed: 21321189
Cell Metab. 2011 Apr 6;13(4):376-388
pubmed: 21459323
Mol Pharmacol. 2011 Nov;80(5):859-69
pubmed: 21803969
J Clin Invest. 2011 Nov;121(11):4477-90
pubmed: 21965330
Hepatology. 2012 Mar;55(3):790-9
pubmed: 21987372
Gastroenterology. 2012 May;142(5):1218-1228.e1
pubmed: 22307032
Science. 2012 Mar 30;335(6076):1638-43
pubmed: 22461615
Cell Metab. 2012 May 2;15(5):725-38
pubmed: 22521878
Cell Metab. 2012 Aug 8;16(2):167-79
pubmed: 22841573
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80
pubmed: 22959249
Acta Biochim Biophys Sin (Shanghai). 2013 Jan;45(1):51-60
pubmed: 23257294
Hepatology. 2013 Oct;58(4):1497-507
pubmed: 23299992
Cell Metab. 2013 Apr 2;17(4):475-90
pubmed: 23562074
Hepatology. 2014 Jan;59(1):143-53
pubmed: 23832510
Mol Cell. 2015 Jul 16;59(2):270-84
pubmed: 26118642
Biochem Soc Trans. 2016 Dec 15;44(6):1675-1682
pubmed: 27913677
Cell. 2017 Mar 9;168(6):960-976
pubmed: 28283069
Mol Metab. 2017 Oct;6(10):1113-1125
pubmed: 29031713